Chronic kidney disease in patients with cardiac disease: A review of evidence-based treatment

Kidney International

Volumn 68, Issue 4, 2005, Pages 1419-1426

  McMurray, John J V ^a  

^a WESTERN INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CANDESARTAN; CAPTOPRIL; CARVEDILOL; CLOPIDOGREL; CREATININE; DIGITALIS; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EZETIMIBE; FLUINDOSTATIN; FUROSEMIDE; GEMFIBROZIL; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOSORBIDE DINITRATE; METOPROLOL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; SPIRONOLACTONE; UNINDEXED DRUG; VALSARTAN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CREATININE BLOOD LEVEL; DEFIBRILLATOR; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HEART FAILURE; HEART INFARCTION; HEART INFARCTION PREVENTION; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK REDUCTION; SECONDARY PREVENTION; STABLE ANGINA PECTORIS; STOMACH HEMORRHAGE; STOMACH IRRITATION; THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME;

EVIDENCE-BASED MEDICINE; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIAL INFARCTION; RENAL INSUFFICIENCY, CHRONIC;

EID: 31644432097     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00552.x     Document Type: Conference Paper

References (82)

1. VLAGOPOULOS PT, SARNAK MJ: Traditional and nontraditional cardiovascular risk factors in chronic kidney disease. Med Clin North Am 89:587-611, 2005
2. ANAVEKAR NS, PFEFFER MA: Cardiovascular risk in chronic kidney disease. Kidney Int (Suppl 92):S11-S15, 2004
3. BEST PJ, REDDAN DN, BERGER PB, et al: Cardiovascular disease and chronic kidney disease: Insights and an update. Am Heart J 148:230-242, 2004
4. SHLIPAK MG, SARNAK MJ, KATZ R, et al: Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 352:2049-2060, 2005
5. CULLETON BF, LARSON MG, WILSON PW, et al: Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 56:2214-2219, 1999
6. SHLIPAK MG, SMITH GL, RATHORE SS, et al: Renal function, digoxin therapy, and heart failure outcomes: Evidence from the digoxin intervention group trial. J Am Soc Nephrol 15:2195-2203, 2004
7. SMILDE TD, HILLEGE HL, VOORS AA, et al: Prognostic importance of renal function in patients with early heart failure and mild left ventricular dysfunction. Am J Cardiol 94:240-243, 2004
8. MCALISTER FA, EZEKOWITZ J, TONELLI M, ARMSTRONG PW: Renal insufficiency and heart failure: Prognostic and therapeutic implications from a prospective cohort study. Circulation 109:1004-1009, 2004
9. MCCLELLAN WM, FLANDERS WD, LANGSTON RD, et al: Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol 13:1928-1936, 2002
10. EZEKOWTTZ J, MCALLISTER FA, HUMPHRIES KH, et al: APPROACH Investigators. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol 44:1587-1592, 2004
11. AL-AHMAD A, RAND WM, MANJUNATH G, et al: Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 38:955-962, 2001
12. DRIES DL, EXNER DV, DOMANSKI MJ, et al: The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 35:681-689, 2000
13. [No authors listed]: Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 316:1429-1435, 1987
14. LJUNGMAN S, KJEKSHUS J, SWEDBERG K: Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial). Am J Cardiol 70:479-487, 1992
15. MAGGIONI AP, ANAND I, GOTTLIEB SO, et al: Val-HeFT Investigators (Valsartan Heart Failure Trial). Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 40:1414-1421, 2002
16. GRANGER CB, MCMURRAY JJ, YUSUF S, et al: CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting- enzyme inhibitors: the CHARM-Alternative trial. Lancet 362:772-776, 2003
17. PACKER M, BRISTOW MR, COHN JN, et al: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 334:1349-1355, 1996
18. PACKER M, FOWLER MB, ROECKER EB, et al: Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: Results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106:2194-2199, 2002
19. PACKER M, COATS AJ, FOWLER MB, et al: Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651-1658, 2001
20. [No authors listed]: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HP). Lancet 12:2001-2007, 1999
21. POOLE-WILSON PA, SWEDBERG K, CLELAND JG, et al: Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): Randomised controlled trial. Lancet 362:7-13, 2003
22. FLATHER MD, SHIBATA MC, COATS AJ, et al: SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26:215-225, 2005
23. [No authors listed]: The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 353:9-13, 1999
24. ERDMANN E, LECHAT P, VERKENNE P, WIEMANN H: Results from post-hoc analyses of the CIBIS II trial: Effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail 3:469-479, 2001
25. CICE G, FERRARA L, D'ANDREA A, D'ISA S, DI BENEDETTO A, CITTADINI A, RUSSO PE, GOLINO P, CALABRO R: Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: A prospective, placebo-controlled trial. J Am Coll Cardiol 41:1438-1444, 2003
26. MCMURRAY JJ, OSTERGREN J, SWEDBERG K, et al: CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial. Lancet 362:767-771, 2003
27. PITT B, ZANNAD F, REMME WJ, et al: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709-717, 1999
28. JUURLINK DN, MAMDANI MM, LEE DS, et al: Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351:543-551, 2004
29. MASOUDI FA, GROSS CP, WANG Y, et al: Adoption of Spironolactone Therapy for Older Patients With Heart Failure and Left Ventricular Systolic Dysfunction in the United States. 1998-2001. Circulation 2005 [Jun 27, Epub ahead of print]
30. CARSON P, ZIESCHE S, JOHNSON G, COHN JN: Racial differences in response to therapy for heart failure: Analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail 5:178-187, 1999
31. EXNER DV, DRIES DL, DOMANSKI MJ, COHN JN: Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 344:1351-1357, 2001
32. DRIES DL, EXNER DV, GERSH BJ, et al: Racial differences in the outcome of left ventricular dysfunction. N Engl J Med 340:609-616, 1999
33. TAYLOR AL, ZIESCHE S, YANCY C, et al: African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 351:2049-2057, 2004
34. COHN JN, JOHNSON G, ZIESCHE S, et al: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325:303-310, 1991
35. [No authors listed]: The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med 336:525-533, 1997
36. CLELAND JG, DAUBERT JC, ERDMANN E, et al: CARE-HF study Steering Committee and Investigators. Baseline characteristics of patients recruited into the CARE-HF study. Eur J Heart Fail 7:205-214, 2005
37. CLELAND JG, DAUBERT JC, ERDMANN E, et al: Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352:1539-1549, 2005
38. BRISTOW MR, SAXON LA, BOEHMER J, et al: Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350:2140-2150, 2004
39. MCCULLOUGH PA, HASSAN SA, PALLEKONDA V, et al: Bundle branch block patterns, age, renal dysfunction, and heart failure mortality. Int J Cardiol 102:303-308, 2005
40. BARDY GH, LEE KL, MARK DB, et al: Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352:225-237, 2005
41. YUSUF S, PFEFFER MA, SWEDBERG K, et al: CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. Lancet 362:777-781, 2003
42. ANAVEKAR NS, MCMURRAY JJ, VELAZQUEZ EJ, et al: Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351:1285-1295, 2004
43. HERZOG CA, MA JZ, COLLINS AJ: Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 339:799-805, 1998
44. SHLIPAK MG, HEIDENREICH PA, NOGUCHI H, et al: Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 137:555-562, 2002
45. WRIGHT RS, REEDER GS, HERZOG CA, et al: Acute myocardial infarction and renal dysfunction: A high-risk combination. Ann Intern Med 137:563-570, 2002
46. MASOUDI FA, PLOMONDON ME, MAGID DJ, et al: Renal insufficiency and mortality from acute coronary syndromes. Am Heart J 147:623-629, 2004
47. KIRTANE AJ, LEDER DM, WAIKAR SS, et al: TIMI Study Group. Serum blood urea nitrogen as an independent marker of subsequent mortality among patients with acute coronary syndromes and normal to mildly reduced glomerular filtration rates. J Am Coll Cardiol 45:1781-1786, 2005
48. SANTOPINTO JJ, Fox KA, GOLDBERG RJ, et al: GRACE Investigators. Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: Findings from the global registry of acute coronary events (GRACE). Heart 89:1003-1008, 2003
49. GIBSON CM, PINTO DS, MURPHY SA, et al: TIMI Study Group. Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. J Am Coll Cardiol 42:1535-1543, 2003
50. WISON S, FOO K, CUNNINGHAM J, et al: Renal function and risk stratification in acute coronary syndromes. Am J Cardiol 91:1051-1054, 2003
51. FREEMANTLE N, CLELAND J, YOUNG P, et al: Beta Blockade after myocardial infarction: systematic review and meta regression analysis. Br Med J 318:1730-1737, 1999
52. ANTITHROMBOTIC TRIALISTS' COLLABORATION: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 324:71-86, 2002
53. FERNANDEZ JS, SADANIANTZ BT, SADANIANTZ A: Review of antithrombotic agents used for acute coronary syndromes in renal patients. Am J Kidney Dis 42:446-455, 2003
54. BAIGENT C, LANDRAY M, LEAPER C, et al: First United Kingdom Heart and Renal Protection (UK-HARP-I) study: Biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis 45: 473-484, 2005
55. [No authors listed]: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 348:1329-1339, 1996
56. YUSUF S, ZHAO F, MEHTA SR, et al: Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494-502, 2001
57. FLATHER MD, YUSUF S, KOBER L, et al: Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-inhibitor Myocardial Infarction Collaborative Group. Lancet 355:1575-1581, 2000
58. PFEFFER MA, BRAUNWALD E, MOYE LA, et al: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327:669-677, 1992
59. TOKMAKOVA MP, SKALI H, KENCHAIAH S, et al: Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: The Survival And Ventricular Enlargement (SAVE) study. Circulation 110:3667-3673, 2004
60. YUSUF S, SLEIGHT P, POGUE J, et al: Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342:145-153, 2000
61. MANN JF, GERSTEIN HC, POGUE J, et al: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial. Ann Intern Med 134:629-636, 2001
62. PFEFFER MA, MCMURRAY JJ, VELAZQUEZ EJ, et al: Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349:1893-1906, 2003
63. TONELLI M, ISLES C, CURHAN GC, et al: Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 110:1557-1563, 2004
64. TONELLI M, MOYE L, SACKS FM, et al: Cholesterol and Recurrent Events (CARE) Trial Investigators. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 138:98-104, 2003
65. TONELLI M, MOYE L, SACKS FM, et al: Cholesterol and Recurrent Events Trial Investigators. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 14:1605-1613, 2003
66. COLHOUN HM, BETTERIDGE DJ, DURRINGTON PN, et al, CARDS investigators: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet 364:685-696, 2004
67. SEVER PS, DAHLOF B, POULTER NR, et al, ASCOT investigators: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 361:1149-1158, 2003
68. HEART PROTECTION STUDY COLLABORATIVE GROUP: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 360:7-22, 2002
69. HOLDAAS H, FELLSTROM B, JARDINE AG, et al: Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial. Lancet 361:2024-2031, 2003
70. BAIGENT C, LANDRY M: Study of Heart and Renal Protection (SHARP). Kidney Int (Suppl 84):S207-S10, 2003
71. FELLSTROM B, ZANNAD F, SCHMIEDER R, et al: Effect of rosuvastatin on outcomes in chronic haemodialysis patients - Design and rationale of the AURORA study. Curr Control Trials Cardiovasc Med 6:9, 2005
72. TONELLI M, COLLINS D, ROBINS S, et al. Veterans' Affairs High-Density Lipoprotein Intervention Trial (VA-HIT) Investigators. Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency. Kidney Int 66:1123-1130, 2004
73. PITT B, REMME W, ZANNAD F, et al: Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309-1321, 2003
74. STIGANT C, IZADNEGAHDAR M, LEVIN A, et al: Outcomes after percutaneous coronary interventions in patients with CKD: Improved outcome in the stenting era. Am J Kidney Dis 45:1002-1009, 2005
75. PITT B: Revascularization in patients with chronic kidney disease: The state of the ARTS. Eur Heart J 2005 [May 25. Epub ahead of print]
76. MCCULLOUGH PA: Evaluation and treatment of coronary artery disease in patients with end-stage renal disease. Kidney Int (Suppl 95):S51-S58, 2005
77. O'HANLON R, REDDAN DN: Treatment of acute coronary syndromes in patients who have chronic kidney disease. Med Clin North Am 89:563-585, 2005
78. GIBSON CM, DUMAINE RL, GELFAND EV, et al: TIMI Study Group. Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome: observations in 13.307 patients in five TIMI trials. Eur Heart J 25:1998-2005, 2004
79. MENON V, SARNAK MJ, LESSARD D, GOLDBERG RJ: Recent trends in hospital management practices and prognosis after acute myocardial infarction in patients with kidney disease. Am J Cardiol 94:1290-1293, 2004
80. K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients. Am J Kidney Dis 45(3 Pt 2):16-153, 2005
81. SARNAK MJ, LEVEY AS, SCHOOLWERTH AC, et al, American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108:2154-2169, 2003
82. MCCULLOUGH PA, SANDBERG KR, BORZAK S, et al: Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. Am Heart J 144:226-232, 2002